de Vries EGE - Search Results

1

RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.

van Helden EJ, Angus L, Menke-van der Houven van Oordt CW, Heideman DAM, Boon E, van Es SC, Radema SA, van Herpen CML, de Groot DJA, de Vries EGE, Jansen MPHM, Sleijfer S, Verheul HMW. van Helden EJ, et al. Among authors: de vries ege, de groot dja. Mol Oncol. 2019 Nov;13(11):2361-2374. doi: 10.1002/1878-0261.12550. Epub 2019 Sep 30. Mol Oncol. 2019. PMID: 31350822 Free PMC article.

2

Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis.

Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, de Jong S. Hougardy BM, et al. Int J Cancer. 2006 Apr 15;118(8):1892-900. doi: 10.1002/ijc.21580. Int J Cancer. 2006. PMID: 16287099

3

Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.

van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ. van Geelen CM, et al. J Clin Oncol. 2006 Nov 1;24(31):4998-5004. doi: 10.1200/JCO.2006.06.8809. J Clin Oncol. 2006. PMID: 17075118

4

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S. Mom CH, et al. Clin Cancer Res. 2009 Sep 1;15(17):5584-90. doi: 10.1158/1078-0432.CCR-09-0996. Epub 2009 Aug 18. Clin Cancer Res. 2009. PMID: 19690193 Clinical Trial.

5

Perspectives for tailored chemoprevention and treatment of colorectal cancer in Lynch syndrome.

Heijink DM, de Vries EG, Koornstra JJ, Hospers GA, Hofstra RM, van Vugt MA, de Jong S, Kleibeuker JH. Heijink DM, et al. Crit Rev Oncol Hematol. 2011 Nov;80(2):264-77. doi: 10.1016/j.critrevonc.2010.11.009. Epub 2010 Dec 14. Crit Rev Oncol Hematol. 2011. PMID: 21159521 Review.

6

89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.

Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, Hollema H, de Jong JR, de Jong IJ, de Haas S, Scherer SJ, Sluiter WJ, Dierckx RA, Bongaerts AH, Gietema JA, de Vries EG. Oosting SF, et al. J Nucl Med. 2015 Jan;56(1):63-9. doi: 10.2967/jnumed.114.144840. Epub 2014 Dec 4. J Nucl Med. 2015. PMID: 25476536 Free article.

7

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.

Lamberts LE, de Groot DJ, Bense RD, de Vries EG, Fehrmann RS. Lamberts LE, et al. Oncotarget. 2015 Sep 29;6(29):28164-72. doi: 10.18632/oncotarget.4461. Oncotarget. 2015. PMID: 26172299 Free PMC article.

8

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG. Lamberts LE, et al. Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589435

9

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Weekes CD, et al. Mol Cancer Ther. 2016 Mar;15(3):439-47. doi: 10.1158/1535-7163.MCT-15-0693. Epub 2016 Jan 28. Mol Cancer Ther. 2016. PMID: 26823490 Clinical Trial.

10

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.

van Es SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, Elias SG, Boellaard R, Hospers GA, Schröder CP, de Vries EG. van Es SC, et al. J Nucl Med. 2016 Feb;57 Suppl 1:96S-104S. doi: 10.2967/jnumed.115.157974. J Nucl Med. 2016. PMID: 26834109 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

561 results

Search Page

Filters